This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Participants willing and able to provide informed consent
Participants on inhaled treprostinil
Idiopathic interstitial pneumonia (IIP)
Chronic hypersensitivity pneumonitis
Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Exacerbation of underlying lung disease within 28 days prior to randomization.
Initiation of pulmonary rehabilitation within 28 days prior to randomization.
Receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
Pulmovant, Inc.
Lead sponsor